SCHEMBL4493385

SCHEMBL4493385

C=CCC(C#N)(CC(=O)NCc1ccc(F)cc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.44
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
MAOB P27338 1/20 0.42
MCL1 Q07820 1/20 0.42
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 3/20 0.41
THRB P10828 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PLA2G1B P04054 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
MEN1 O00255 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482561 0.76 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HTTKMT2ACYP2C19
SCHEMBL4496567 0.73 ALDH1A1 (0.45) ALDH1A1HPGDSMN1; SMN2HTTPOLB
SCHEMBL10624241 0.71 ALDH1A1 (0.48) ALDH1A1RAB9ASMN1; SMN2HTTKMT2A
SCHEMBL8031705 0.68 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNAHTTKMT2A
SCHEMBL8031703 0.68 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNAHTTKMT2A
SCHEMBL8031704 0.68 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNAHTTKMT2A
SCHEMBL2264964 0.67 MCL1 (0.70) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL28992212 0.67 ALDH1A1 (1.00) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL15562668 0.67 HPGD (1.00) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA
SCHEMBL5861356 0.67 ALDH1A1 (1.00) ALDH1A1HPGDRAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7619086-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-11-17 US disclosed
US-20080139579-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-06-12 US disclosed
EP-1725535-A2 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005086700-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139579-A1 Hiv Integrase Inhibitors INTS9, CDK9, PRDM9 ALDH1A1 3596/4885HPGD 4046/4885RAB9A 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.